Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN 주식 보고서

시가총액: US$5.6m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cyclerion Therapeutics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기no data
CEO 소유권n/a
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간3.5yrs

최근 관리 업데이트

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

CEO

Cyclerion Therapeutics 에는 CEO가 없거나 그에 대한 데이터가 없습니다.


이사회 구성원

이름위치테뉴어보상소유권
Terrance McGuire
Independent Director5.3yrsUS$27.60k0.24%
$ 13.3k
Peter Hecht
Director5.3yrsUS$169.80k15.1%
$ 851.0k
Errol De Souza
Independent Chairman3.3yrsUS$131.08k2%
$ 112.8k
Steven Hyman
Independent Director2yrsUS$57.30k0.80%
$ 45.1k
Michael Higgins
Independent Directorless than a yearUS$43.60k0.80%
$ 45.1k
Robert Malenka
Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
Daniela Salvemini
Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
Mark Currie
Chair of Scientific Advisory Boardno dataUS$366.78k데이터 없음
Andrew Budson
Member of Clinical Advisory Board3.5yrs데이터 없음데이터 없음
Eric Smith
Member of Clinical Advisory Board3.5yrs데이터 없음데이터 없음
M Westover
Member of Clinical Advisory Board3.5yrs데이터 없음데이터 없음
David Salat
Member of Clinical Advisory Board3.5yrs데이터 없음데이터 없음

3.5yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: CYCN 의 이사회경험(평균 재직 기간 3.4 년)으로 간주됩니다.